HUTCHMED (China) Ltd ADR HCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HCM is a good fit for your portfolio.
News
-
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
-
HUTCHMED to Announce 2024 Half-Year Financial Results
-
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
-
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
-
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
-
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
-
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
-
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
Trading Information
- Previous Close Price
- $18.01
- Day Range
- $18.01–18.56
- 52-Week Range
- $11.93–21.92
- Bid/Ask
- $18.50 / $19.12
- Market Cap
- $3.17 Bil
- Volume/Avg
- 29,933 / 136,258
Key Statistics
- Price/Earnings (Normalized)
- 32.35
- Price/Sales
- 3.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.13%
Company Profile
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,990
- Website
- https://www.hutch-med.com
Comparables
Valuation
|
Metric
|
HCM
|
06628
|
06855
|
|---|---|---|---|
Price/Earnings (Normalized) | 32.35 | — | — |
Price/Book Value | 4.34 | 0.57 | 117.64 |
Price/Sales | 3.85 | 8.95 | 31.03 |
Price/Cash Flow | 21.78 | — | — |
Price/Earnings
HCM
06628
06855
Financial Strength
|
Metric
|
HCM
|
06628
|
06855
|
|---|---|---|---|
Quick Ratio | 2.58 | 1.09 | 2.73 |
Current Ratio | 2.72 | 1.23 | 2.74 |
Interest Coverage | 30.20 | −28.87 | −9.36 |
Quick Ratio
HCM
06628
06855
Profitability
|
Metric
|
HCM
|
06628
|
06855
|
|---|---|---|---|
Return on Assets (Normalized) | 11.29% | −22.79% | −30.37% |
Return on Equity (Normalized) | 19.17% | −38.31% | −142.24% |
Return on Invested Capital (Normalized) | 13.58% | −26.22% | −35.31% |
Return on Assets
HCM
06628
06855
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Bgrsprmp | Hry | $82.5 Bil | |||
| Merck KGaA ADR
MKKGY
| Hrsdtkcvv | Dwlthfm | $73.2 Bil | |||
| Haleon PLC ADR
HLN
| Xkzjfljs | Psy | $41.0 Bil | |||
| Viatris Inc
VTRS
| Hshnyngg | Rsmj | $14.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Yzkkhshl | Qjxkk | $13.7 Bil | |||
| Catalent Inc
CTLT
| Vbjmgpcyh | Kxyvvbg | $10.6 Bil | |||
| Perrigo Co PLC
PRGO
| Kpdgzlnd | Zqcm | $3.8 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Zhprqrhl | Jbggxr | $3.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Qnmcdxp | Kdmf | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Fshgfxztfc | Drq | $2.7 Bil |